Functional Impairment and Painful Physical Symptoms in Patients with Major Depressive Disorder Treated with Antidepressants: Real-World Evidence from the Middle East
Jihyung Hong1, *, Diego Novick2, Maria Victoria Moneta3, Ahmed El-Shafei4, Héctor Dueñas5, Josep Maria Haro3
Identifiers and Pagination:Year: 2017
First Page: 145
Last Page: 155
Publisher Id: CPEMH-13-145
Article History:Received Date: 01/4/2017
Revision Received Date: 9/8/2017
Acceptance Date: 24/08/2017
Electronic publication date: 30/09/2017
Collection year: 2017
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The Global Burden of Disease 2010 study reported the relative size of major depressive disorder (MDD) burden to be greater in the Middle East and North Africa than anywhere else. However, little research has been carried out to examine the comparative effectiveness of antidepressants in this region.
To assess and compare functioning levels in Middle Eastern patients with MDD treated with either duloxetine or a selective serotonin reuptake inhibitor (SSRI), and to examine the impacts of depression-related pain on functioning by the type of treatment.
This post-hoc analysis, which focused on Middle Eastern patients, used data from a 6-month prospective observational study that included 1,549 MDD patients without sexual dysfunction. Levels of functional impairment and depression-related pain were assessed using the Sheehan Disability Scale (SDS) and the modified Somatic Symptom Inventory, respectively. A mixed model with repeated measures (MMRM) was employed.
The mean age of the patients was 37.3 (SD=8.4) years, and 34.6% were female. Patient functioning was, on average, moderately impaired at baseline, but improved substantially during follow-up in both the duloxetine (n=152) and the SSRI (n=123) cohorts. The MMRM results showed a lower level of functional impairment at 24 weeks in the duloxetine cohort than in the SSRI cohort (p<0.001). Pain severity at baseline was positively associated with functional impairment during follow-up only in the SSRI cohort (p=0.003).
Duloxetine-treated MDD patients achieved better functioning than SSRI-treated patients. This treatment difference was partly driven by depression-related pain.
Depression is one of the most prevalent, disabling and costly mental illnesses, currently affecting over 300 million people worldwide . According to the World Mental Health (WHM) survey conducted in 18 countries, the life-time prevalence of major depressive episode (MDE) was found to be up to 21%. The survey also revealed a great variation in the prevalence of MDE across different countries – it tended to be higher in some Western countries but lower in Asian and Middle Eastern countries. For instance, it was found to be 19.2% in the United States and 21.0% in France but 6.5% in China, 6.6% in Japan and 10.9% in Lebanon - the only Arab country included in the survey . However, these estimates are based on data from 2001-2007, and emerging evidence suggests that the prevalence of depression in these latter countries is probably higher than what is reported in the survey. For example, the 2010 Global Burden of Disease (GBD) study reported the relative size of major depressive disorder (MDD) burden, measured in disability adjusted life years (DALYs), to be greater in the Middle East and North Africa (MENA) than anywhere else, particularly in women in this region [3, 4]. Unfortunately, this high level of MDD burden is expected to continue because wars and conflicts in the MENA region are likely to further increase the prevalence and the burden of MDD .
The high level of DALYs due to depression, which accounts for nearly half (40.5%) of the total DALYs associated with mental and substance use disorders , translates into a substantial economic burden of the disease. Although such estimates are not available in the MENA region, the total costs of depression were estimated to be about ¥2 trillion (about US$20 billion) in Japan (2005 value) , over US$6 billion in China (2002 value) , and over US$4 billion in South Korea (2005 value) . Notably, indirect costs associated with lost productivity far exceeded direct medical costs of depression in all studies. This implies that patients with depression have substantial impairment in functioning and health-related quality of life (HRQoL).
Indeed, nearly two-thirds of MDD patients were reported to have severe impairment in functioning and HRQoL, respectively [10, 11]. Such impairment may be even more pronounced in countries, for instance those of the MENA region, where access to mental health care is severely limited due to the strong stigma attached to mental illness . Furthermore, a high proportion of psychiatric patients also tend to somatise their emotional problems and communicate them in the form of physical symptoms in such cultures . Many of them seek help first from primary care physicians and present to them with physical complaints such as headache, heart/chest pain, back pain, and abdominal pain, rather than psychological complaints. These physical symptoms, either as a manifestation of MDD or as a coexisting condition, not only delay the diagnosis and treatment of MDD but also further interfere with daily functioning and HRQoL in patients with MDD [14, 15].
Duloxetine hydrochloride is a potent and relatively balanced inhibitor of serotonin and norepinephrine reuptake (SNRI) . It has been approved not only for the management of MDD and generalised anxiety disorder but also for pain-related conditions (chronic musculoskeletal pain, fibromyalgia, and diabetic peripheral neuropathic pain) in the United States. It has also been approved for some or all of them in many other countries, including the countries of the MENA region. Limited evidence, mostly from the United States and Europe, suggests that the dual action of SNRIs may more effectively control the symptoms of depression than those antidepressants inhibiting only one monoamine at least for the subgroup of MDD patients with concomitant pain [17-19]. This is because the pathophysiology of both conditions likely involve an imbalance of serotonin and norepinephrine . More research is needed to establish this hypothesis, especially in the MENA region, where the effects of such agents have never been evaluated .
This post-hoc study aimed to assess and compare the level of functional impairment over time in MDD patients treated with either duloxetine or a selective serotonin reuptake inhibitor (SSRI) for up to 6 months in actual clinical settings in Saudi Arabia and the United Arab Emirates (UAE), using data from an international prospective observational study. This study also examined whether the impacts of depression-related pain on functioning varied with the type of treatment.
2. MATERIAL AND METHODS
2.1. Study Design
This study used data from a 6-month, multi-national, prospective, non-interventional, observational study. It was primarily designed to examine treatment-emergent sexual dysfunction (TESD) and other treatment outcomes among patients with MDD who were treated with either an SNRI or a selective serotonin reuptake inhibitor (SSRI) in actual clinical practice. A total of 1,549 patients, out of 1,647 patients who were enrolled between Nov 2007 and Nov 2008, were classified as “sexually active patients without sexual dysfunction at study entry”. This post-hoc study focused only on those patients from the Middle East (n=314) (Saudi Arabia [n=179] and United Arab Emirates (UAE) [n=135]).
This study followed the ethical standards of responsible local committees and the regulations of the participating countries. Ethical review board (ERB) approval was obtained as required by local laws. All patients provided informed consent for the provision and collection of the data. This study was also conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Pharmacoepidemology Practices (GPPs), as well as applicable laws and regulations of the countries where the study was conducted, as appropriate.
2.2. Study Sample
Patients were eligible to participate in the study if they met the following inclusion criteria: (1) at least 18 years of age; (2) presenting with an episode of MDD in an outpatient setting, with MDD diagnosed according to the International Statistical Classification of Diseases 10th revision (ICD-10) or Diagnostic and Statistical Manual of Mental Disorders-4th edition text revision (DSM-IV-TR)  criteria; (3) the Clinical Global Impression-Severity (CGI-S) score of ≥4 (i.e., at least moderately ill) ; (4) initiating or switching to any available SSRI or SNRI antidepressant in accordance with a treating psychiatrist’s discretion; (5) being sexually active without sexual dysfunction, as defined by Arizona Sexual Experience Scale (ASEX) ; and (6) providing consent to release data. The study excluded patients who (1) were participating in another study; (2) had a history of treatment-resistant depression; (3) had a past or current diagnosis of schizophrenia, schizophreniform or schizoaffective disorder, bipolar disorder, dysthymia, mental retardation or dementia; or (4) received any antidepressant within 1 week (1 month for fluoxetine) prior to study entry, with the exception of patients receiving an ineffective treatment for whom the immediate switch to an SSRI or an SNRI antidepressant was considered to be the best treatment option.
Patients were, however, not required to continue their initial medications. Changes in medication and dosing were possible at any time during follow-up, as determined by their treating psychiatrist.
2.3. Data Collection and Outcome Assessment
Data were collected during visits within the normal course of care. Subsequent data collection was targeted at week 8, week 16, and week 24 from the baseline visit (i.e., study entry). Patient socio-demographics and clinical history were recorded at the baseline assessment. Clinical severity of depression was assessed at each visit using the CGI-S  and the 16-item Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR16) .
Functional impairment was also assessed at each visit using the Sheehan Disability Scale (SDS) . It is a brief self-report inventory that assesses functional impairment in work/school, social life, and family life. The level of functional impairment in each of the three domains is rated from 0 to 10. The level of global functional impairment is determined with the sum of the three subscores. A higher score indicates a higher level of functional impairment.
Depression-related pain severity was measured using the pain-related items of the Somatic Symptom Inventory (SSI), which includes headaches, heart/chest pain, neck pain, abdominal pain, lower back pain, joint pain, and muscular soreness . PPS status was also assessed as painful physical symptom negative (PPS-) or positive (PPS+); PPS+ was defined as a mean score of at least 2 for the seven pain-related items of the SSI.
2.4. Statistical Analysis
This post-hoc study included 275 patients, out of the 314 patients from Saudi Arabia and UAE, who (1) initiated either duloxetine or an SSRI as monotherapy at baseline, and (2) who had non-missing data on the QIDS-SR16 score at baseline with at least one non-missing QIDS-SR16 score during follow-up (n=152 in the duloxetine cohort and n=123 in the SSRI cohort). This study analysed the patient observations up to the point where their initial medications were discontinued (n=127 [83.6%] in the duloxetine cohort and n=97 [78.9%] in the SSRI cohort available at 24 weeks).
The baseline socio-demographic and clinical characteristics of the two treatment cohorts were summarised and compared using the Chi-square test (for categorical variables) and the Mann-Whitney test (for continuous variables). The level of functional impairment (both SDS total scores and SDS subscores) at each visit was also described and compared using the Mann-Whitney test. The treatment difference in functional impairment at each visit was also expressed in terms of the effect size, using Cohen’s d .
The mixed effects models for repeated measures (MMRM) analysis was used to estimate and compare the levels of functional impairment (SDS total, work, social life, and family life) during follow-up between the two treatment groups. The models were adjusted for age, gender, SSI-pain score at baseline, QIDS-SR16 score at baseline, the baseline value of the outcome modelled, and visit number. The models were further adjusted for the following variables if they appeared to be significant (p<0.1) when each one of them was added to the above model: independent living (living in his/her own house), living with a spouse/partner, employment status, having MDD episodes in the 24 months prior to study entry, MDD hospitalisations in the 24 months prior to study entry, and the number of any significant pre-existing comorbidities. Finally, the models also included the interaction term between time (visit number) and treatment if it appeared to be significant (p<0.05) in the full model.
All analyses were repeated for each subgroup of patients treated with duloxetine and SSRIs to examine whether the association between depression-related pain (SSI-pain score) and functional impairment (SDS total score) was mediated or moderated by the type of treatment. In addition, the MMRM analysis was further conducted to compare the impacts of duloxetine and SSRIs on depression-related pain during follow-up. The same list of independent variables aforementioned were considered in the model.
All statistical analyses were performed using SAS version 9.3 for Windows (SAS Institute, Cary, NC, USA).
3.1. The Characteristics of Patients at Baseline
A total of 275 patients were included in the final analysis. Overall, the mean (standard deviation [SD]) age of these patients was 37.3 (SD=8.4) years, and only about one-third of them (34.6%) were female (27.1% in Saudi Arabia and 44.2% in the UAE, p=0.003). Slightly more than half of the patients (56.4%) were from Saudi Arabia, and the rest were from the UAE (43.6%). The majority of the patients (76.7%) were living with a spouse. About two-thirds of the patients (67.3%) had full-time employment, and more than half of the patients (57.8%) completed at least a tertiary or university degree. In addition, nearly two-thirds of these MDD patients (61.5%) also suffered from PPS at baseline. Only 20% of MDD patients had taken antidepressants, and 48.4% (21.1% for benzodiazepines and the 27.3% for other medications) had taken other psychiatric medications in the previous 24 months.
Of the 275 patients, 152 initiated duloxetine at baseline and the rest (n=123) initiated an SSRI antidepressant at baseline. The most common SSRIs prescribed at baseline were escitalopram (38.2%), paroxetine (27.6%), and sertraline (20.3%). The median daily doses (interquartile ranges [IQRs]) of these antidepressants at baseline were 10.0mg/d (IQR: 10.0mg/d – 10.0mg/d) for escitalopram, 22.5mg/d (IQR: 20.0mg/d – 25.0mg/d) for paroxetine, 50.0mg/d (IQR: 50.0mg/d – 100.0mg/d) for sertraline, and 60.0mg/d (60.0mg/d – 60.0mg/d) for duloxetine.
Table (1) summarises the baseline patient characteristics by treatment cohorts. A higher proportion of the SSRI cohort were female (p=0.015) and from the UAE (p=0.003), whereas a higher proportion of the duloxetine cohort had completed a tertiary or university degree (p=0.013). In addition, a higher proportion of the SSRI cohort had taken other psychiatric medications in the previous 24 months (37.4% vs. 19.1%), whereas a higher proportion of the duloxetine cohort had taken benzodiazepines in the previous 24 months (26.3% vs. 14.6%) (p=0.001). Nevertheless, the levels of depression severity and depression-related pain at baseline were similar for the two cohorts, and the proportion of patients exhibiting PPS at baseline was also similar for the two (63.8% in the duloxetine cohort and 58.5% in the SSRI cohort, p=0.371).
|Baseline Characteristic||Duloxetine(n=152)||SSRI (n=123)||P-value|
|Age, Mean (SD)||36.9 (7.9)||37.7 (9.1)||0.673|
|United Arab Emirates, %||35.5||53.7||0.003|
|Age at First Symptoms of MDD, Mean (SD)||31.5 (7.3)||31.3 (8.6)||0.787|
|BMI (kg/m2), Mean (SD)||26.9 (4.2)||26.5 (4.1)||0.582|
|Living with a Spouse, %||77.0||76.4||0.838|
|Independent Living, %||13.8||15.4||0.703|
|Level of Education, %||-||-||0.013|
|University or More||63.8||50.4||-|
|Secondary School/Occupational Programme||32.2||37.4||-|
|Primary School or Less||3.9||12.2||-|
|CGI-S, Mean (SD)||4.5 (0.6)||4.5 (0.6)||0.310|
|QIDS-SR16, Mean (SD)||12.6 (4.5)||12.0 (4.9)||0.234|
|SSI-pain, Mean (SD)||15.7 (4.9)||14.7 (4.9)||0.098|
|Painful Physical Symptoms, %||63.8||58.5||0.371|
|Number of Comorbidities, %||-||-||0.050|
|Had MDD Episodes in the Past 24 Months, %||78.9||82.1||0.511|
|Had been Hospitalised for MDD in the Past 24 Months, %||2.6||6.5||0.118|
|Had Taken Antidepressants in the Past 24 Months, %||21.1||18.7||0.885|
|Had Taken other Psychiatric Medications in the Past 24 Months, %||-||-||0.001|
3.2. The Level of Functional Impairment over Time by Treatment Cohort
Table (2) demonstrates the mean levels of functional impairment at baseline and at 24 weeks, respectively, by treatment cohort. At baseline, the level of functional impairment was slightly higher in the duloxetine cohort than in the SSRI cohort: the mean SDS total score at baseline was 17.36 (SD=6.00) in the former and 15.66 (SD=6.28) in the latter (p=0.012). Nevertheless, both treatment groups, on average, had a moderate level of functional impairment in all three subdomains (SDS work, social life, and family life), with a mean score of 5.35 (SD=2.66) (for work) to 6.24 (SD=2.16) (for social life) in the duloxetine cohort and 5.11 (SD=2.41) (for work) to 5.35 (SD=2.17) (for social life) in the SSRI cohort.
|SDS Total Score||17.36 (6.00)||15.66 (6.28)||0.012||0.28|
|SDS Work Score||5.35 (2.66)||5.11 (2.41)||0.186||0.09|
|SDS Social Life Score||6.24 (2.16)||5.35 (2.17)||<0.001||0.41|
|SDS Family Life Score||5.77 (2.29)||5.20 (2.19)||0.019||0.25|
|At 24 weeks|
|SDS Total Score||3.41 (3.06)||4.60 (3.21)||0.008||-0.38|
|SDS Work Score||1.09 (1.23)||1.67 (1.27)||0.001||-0.47|
|SDS Social Life Score||1.24 (1.04)||1.51 (1.11)||0.087||-0.25|
|SDS Family Life Score||1.08 (1.01)||1.41 (1.04)||0.024||-0.32|
Despite a higher level of baseline functional impairment, the duloxetine cohort achieved a greater level of functioning at 24 weeks, compared to the SSRI cohort. At 24 weeks, the mean SDS total score was 3.41 (SD=3.06) in the former and 4.60 (SD=3.21) in the latter (p=0.008). Similar patterns were also observed in all three SDS subdomains. This treatment difference was equivalent to the effect size of -0.38 for SDS total (subdomains: -0.25 for SDS social life to -0.47 for SDS work).
The level of functional impairment at 24 weeks was still lower in the duloxetine cohort than in the SSRI cohort even when the adjustment of baseline differences was made through the MMRM, as shown in Table (3) and Fig. (1). At 24 weeks, the estimated mean SDS total score (i.e., least squares [LS] means) was 3.13 (standard error [SE]=0.26) in the former, which was lower than that of 4.96 (SE=0.29) in the latter (p<0.001) (i.e. better functioning in the duloxetine cohort) (Fig. 1).
|Female (vs. male)||-0.31||0.39||0.421|
|QIDS-SR16 Score at Baseline||-0.31||0.06||<0.001|
|SSI-Pain Score at Baseline||0.10||0.05||0.030|
|SDS Total Score at Baseline||0.31||0.03||<0.001|
|Duloxetine (vs. SSRI)a||-0.25||0.64||0.697|
|Weeks (vs. Week 8)a|
|Duloxetine at Week 16||-0.58||0.58||0.324|
|Duloxetine at Week 24||-1.58||0.65||0.015|
|Fig. (1). The estimated SDS total scores during follow-up, by treatment cohorts.|
Notably, the level of depression-related pain at baseline, as measured by SSI-pain scores, was also statistically significantly associated with the level of functional impairment during follow-up (coefficient=0.10, p=0.030). This positive association between the two was even more apparent in the subgroup of SSRI-treated patients (coefficient=0.23, p=0.003), but not in the subgroup of duloxetine-treated patients (coefficient=0.04, p=0.500) (Fig. 2). In relation to this finding, an additional analysis was conducted to confirm the differential impacts of duloxetine and SSRIs on depression-related pain. The MMRM results showed that the level of depression-related pain at 24 weeks was statistically significantly lower in duloxetine-treated patients (LS means [SE]: 8.31 [0.24]) than in SSRI-treated patients (LS means [SE]: 11.14 [0.28]) (p<0.001) (data not shown).
|Fig. (2). The results of MMRM analyses: associations between baseline SSI-pain scores and SDS total scores during follow-up, by treatment cohorts.|
This post-hoc analysis assessed the level of functional impairment over time, using the Sheehan Disability Scale , in the subgroup of Middle Eastern patients with MDD, who were either treated with duloxetine or with an SSRI for up to 6 months in actual clinical practice in Saudi Arabia and the UAE. The results showed that this subgroup of patients had a moderate level of functional impairment in all three SDS subdomains (work, social life, and family life) at baseline, but the patients, particularly those patients treated with duloxetine, achieved better functioning over time in all three subdomains. The findings also highlighted the differential impacts of depression-related pain on functioning by treatment cohorts. The negative impact of baseline pain severity on improvement in functional impairment during follow-up appeared to be moderated by treatment with duloxetine, but not by treatment with SSRIs.
4.1. Effects and Roles of Antidepressants in the Treatment of MDD in The Middle East
Treatment with antidepressants, both duloxetine and SSRIs, was found to be effective in improving functioning of MDD patients in the Middle East. These findings are highly consistent with those of our previous studies with East Asian patients, which examined the effects of duloxetine with a daily dose of ≤ 60mg and SSRIs, respectively, on various clinical and humanistic outcomes [24, 26]. There are, however, no studies in the Middle East to have evaluated the effects of antidepressants in the treatment of MDD, as confirmed in the recent systematic review by Travers et al. . This is rather surprising given the role of antidepressants in modern psychiatry and the high level of MDD burden (in terms of DALYs) reported in this region [3, 4].
No regional treatment guidelines for MDD are available either, except for the two published in a neighbouring country, Turkey [35, 37]. While both Turkish and other international guidelines [38, 39] recommend the use of antidepressants as first-line treatment of MDD, available evidence suggests that the rate of antidepressant use is low, but that of benzodiazepine is relatively high in the treatment of MDD in the Middle East . In our study, 21.1% and 20.0% of the MDD patients were reported to have taken benzodiazepines and antidepressants, respectively, in the 24 months prior to the study entry. The lack of regional clinical evidence might have contributed in part to the absence of treatment guidelines and the lack of appropriate treatments for MDD in this region.
While our study found both duloxetine and SSRIs to be effective in improving functional impairment, duloxetine-treated patients achieved a higher level of functioning than SSRI-treated patients during follow-up. However, the superiority of SNRIs including duloxetine over SSRIs has not been well established in the literature , although limited evidence supports the advantage of SNRIs in subgroups of MDD patients with PPS and/or more severely ill [18, 41]. Notably, the majority of MDD Middle Eastern patients in this study exhibited PPS at baseline (63.8% in the duloxetine cohort and 58.5% in the SSRI cohort, p=0.371).
4.2. Implications of Depression-Related Pain in the Treatment of MDD in the Middle East
Our study also found differential impacts of depression-related pain on functioning by treatment cohorts. Duloxetine-treated patients achieved functioning independently of pain severity, but SSRI-related patients did not. That is, SSRI-treated patients who had a higher level of depression-related pain at baseline did not achieve the same level of functioning as those who had a lower level of depression-related pain at baseline, confirming the negative impact of pain on improvement in functioning in this cohort. This finding adds to the existing evidence that supports the advantages of SNRIs in the subgroup of patients with PPS, as discussed above, and also reaffirms the importance of pain control in the treatment of MDD.
Painful physical symptoms seemingly play dual roles in the treatment of MDD as both a trigger for help-seeking and a risk factor for delayed diagnosis. Its dual role is particularly relevant in the Middle East, where mental illness carries an intense and enduring stigma . Patients in such cultures often tend to somatise their emotional problems and express them in terms of physical symptoms. This may partly explain the high percentage of painful physical symptoms (61.5% at baseline) found in our study, although it is not clear whether this is a manifestation of depressive symptoms or a coexisting pain condition with an unknown aetiology.
Okasha reported that up to 80% of psychiatric patients have a tendency to somatise their emotional and psychiatric problems . Many of these patients therefore do not seek help in a psychiatric setting, but instead present to primary care with physical complaints. This may explain the over-representation of depressed patients in primary care in the Middle East. Using the Beck Depression Inventory, Hamdan et al.  found that nearly half of women attending primary care clinics (n=224) in the UAE were mildly (14.3%), moderately (14.7%), or severely (17.9%) depressed (12). Similarly, Becker et al. reported that about one in five patients attending primary care clinics (n=431) in Saudi Arabia had depression and 67.4% of them were female, using the Patient Health Questionnaire (PHQ) . The authors also suggested that the restrictive Arab culture may have placed women at higher risk for somatic presentations of psychological distress in primary care settings. This postulation is in line with the low proportion of women (34.6%) included in our study, which was conducted in an outpatient psychiatric setting in the region. Becker further examined whether there is a discrepancy in the detection rates of depression and somatisation between primary care physicians and the use of the PHQ screening instrument . The study reported that primary care physicians were aware of psychiatric disorders, but their diagnostic skills for these conditions were poor.
Taken together, a substantial proportion of MDD patients in the Middle East also suffer from painful physical symptoms, which are likely to negatively impact on clinical outcomes, including functioning. Many of these patients tend to seek help first from primary care physicians. It is therefore important to make sure that primary care physicians, who are at the front-line of the healthcare system, correctly diagnose and treat MDD even in the presence of painful physical symptoms.
4.3. Study Limitations
While this study provides meaningful clinical insights into MDD in the Middle East, its findings should be interpreted in the context of the following study limitations. Firstly, data were taken from an observational study. Although the MMRM analysis adjusted for the baseline imbalance between duloxetine- and SSRI-treated patients, there still exists the unobserved imbalance between the two cohorts. Secondly, the primary objective of the observational study was to assess TESD in the treatment of MDD. The study, therefore, included only those patients who were sexually active and did not have sexual dysfunction at baseline. It has been reported that sexual dysfunction is two to three times more prevalent in patients with depression than in the general population [46, 47]. Our findings may therefore not be immediately generalizable to MDD patients as a whole. In addition, sexual dysfunction was measured using the Arizona Sexual Experience Scale . It is not clear whether patients, especially women, were willing to accurately report their sexual dysfunction, particularly in this restrictive culture. Further research is needed to examine whether our findings can be replicated in MDD patients without such inclusion/exclusion criteria. Thirdly, even within the SSRI class, there exist differences in efficacy and/or tolerability between the individual drugs . Therefore, our findings cannot represent the differences in effectiveness, in terms of functional improvement, between duloxetine and any specific SSRIs. Finally, this post-hoc analysis included only 275 patients from the Middle East, and it may therefore not be representative of all patients with MDD in the region. Our results should be interpreted with caution until further replication is available.
Despite its limitations, this study provides some useful clinical insights into the treatment of MDD in the Middle East. Patients treated with duloxetine achieved higher levels of functioning (i.e., global, work, social life, and family life), compared to those treated with SSRIs for the management of MDD in actual clinical settings in the Middle East (Saudi Arabia and the UAE). The study also revealed a high proportion of MDD patients (61.5%) suffering from painful physical symptoms, which was found to negatively impact on functioning. The negative impact of depression-related pain was, however, moderated by treatment with duloxetine, but not by treatment with SSRIs. These findings add to the existing but limited evidence that supports the additional advantage of duloxetine, and possibly SNRIs as a whole, over SSRIs for the treatment of MDD patients presenting with painful physical symptoms. Given the high level of PPS among Middle Eastern MDD patients, it is particularly important to make sure that local primary care physicians, who are at the front-line of the healthcare system, appropriately diagnose and treat MDD patients presenting with physical complaints.
ETHICS APPROVAL AND CONSENT TO PARTICIPATE
Ethical review board (ERB) approval was obtained as required by local laws. All patients provided informed consent for the provision and collection of the data.
HUMAN AND ANIMAL RIGHTS
This study was also conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Pharmacoepidemology Practices (GPPs), as well as applicable laws and regulations of the countries where the study was conducted, as appropriate.
CONSENT FOR PUBLICATION
All authors gave final approval of the version to be published.
CONFLICT OF INTEREST
Jihyung Hong was acted as a consultant for Eli Lilly and Company. Diego Novick, Ahmed El-Shafei, and Héctor Dueñas are employees of Eli Lilly and Company. Josep Maria Haro has acted as a consultant, received grants, or acted as a speaker in activities sponsored by the following companies: Astra-Zeneca, Eli Lilly and Company, Glaxo-Smith-Kline, and Lundbeck. Maria Victoria Moneta conducted the statistical analysis under a contract between Fundació Sant Joan de Déu and Eli Lilly and Company.
The study was funded by Eli Lilly and Company.
|||WHO. Depression. http://www.who.int/mediacentre/factsheets/fs369/en/ 2017. [updated February 2017] (Accessed on 2 MAR 2017).|
|||Kessler RC, Birnbaum HG, Shahly V, et al. Age differences in the prevalence and co-morbidity of DSM-IV major depressive episodes: results from the WHO World Mental Health Survey Initiative. Depress Anxiety 2010; 27(4): 351-64.
|||Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380(9859): 2197-223.
|||Institute for Health Metrics and Evaluation. Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) 2013.|
|||Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med 2013; 10(11): e1001547.
|||Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013; 382(9904): 1575-86.
|||Sado M, Yamauchi K, Kawakami N, et al. Cost of depression among adults in Japan in 2005. Psychiatry Clin Neurosci 2011; 65(5): 442-50.
|||Hu TW, He Y, Zhang M, Chen N. Economic costs of depression in China. Soc Psychiatry Psychiatr Epidemiol 2007; 42(2): 110-6.
|||Chang SM, Hong JP, Cho MJ. Economic burden of depression in South Korea. Soc Psychiatry Psychiatr Epidemiol 2012; 47(5): 683-9.
|||Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289(23): 3095-105.
|||Rapaport MH, Clary C, Fayyad R, Endicott J. Quality-of-life impairment in depressive and anxiety disorders. Am J Psychiatry 2005; 162(6): 1171-8.
|||Hamdan A, Hawamdeh S, Hussein A. The prevalence and correlates of depressive symptoms among Arab women in a primary health care setting. Int J Psychiatry Med 2008; 38(4): 453-67.
|||Al-Krenawi A. Mental health practice in Arab countries. Curr Opin Psychiatry 2005; 18(5): 560-4.
|||Arnow BA, Hunkeler EM, Blasey CM, et al. Comorbid depression, chronic pain, and disability in primary care. Psychosom Med 2006; 68(2): 262-8.
|||Demyttenaere K, Reed C, Quail D, et al. Presence and predictors of pain in depression: Results from the FINDER study. J Affect Disord 2010; 125(1-3): 53-60.
|||Bymaster FP, Lee TC, Knadler MP, Detke MJ, Iyengar S. The dual transporter inhibitor duloxetine: A review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des 2005; 11(12): 1475-93.
|||Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 2007; 62(11): 1217-27.
|||Thase ME, Pritchett YL, Ossanna MJ, Swindle RW, Xu J, Detke MJ. Efficacy of duloxetine and selective serotonin reuptake inhibitors: Comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol 2007; 27(6): 672-6.
|||Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 178: 234-41.
|||Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: A literature review. Arch Intern Med 2003; 163(20): 2433-45.
|||Travers KU, Pokora TD, Cadarette SM, Mould JF. Major depressive disorder in Africa and the Middle East: A systematic literature review. Expert Rev Pharmacoecon Outcomes Res 2013; 13(5): 613-30.
|||Dueñas H, Brnabic AJ, Lee A, et al. Treatment-emergent sexual dysfunction with SSRIs and duloxetine: Effectiveness and functional outcomes over a 6-month observational period. Int J Psychiatry Clin Pract 2011; 15(4): 242-54.
|||Dueñas H, Lee A, Brnabic AJ, et al. Frequency of treatment-emergent sexual dysfunction and treatment effectiveness during SSRI or duloxetine therapy: 8-week data from a 6-month observational study. Int J Psychiatry Clin Pract 2011; 15(2): 80-90.
|||Hong J, Novick D, Montgomery W, Moneta MV, Duenas H, Peng X, et al. Real-world outcomes in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia. Asia-Pac Psychiatry 2015.
|||Novick D, Hong J, Montgomery W, Dueñas H, Gado M, Haro JM. Predictors of remission in the treatment of major depressive disorder: Real-world evidence from a 6-month prospective observational study. Neuropsychiatr Dis Treat 2015; 11: 197-205.
|||Novick D, Montgomery W, Haro JM, et al. Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia. Neuropsychiatr Dis Treat 2016; 12: 383-92.
|||The ICD-10 Classification of Mental and Behavioural Disorders Clinical Descriptions and Diagnostic Guidelines 1992.|
|||APA.. Diagnostic and Statistical Manual of Mental Disorders 2000.|
|||Guy W. ECDEU assessment manual for psychopharmacology (Revised) 1976.|
|||McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): Reliability and validity. J Sex Marital Ther 2000; 26(1): 25-40.
|||Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): A psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003; 54(5): 573-83.
|||Sheehan DV. The Anxiety Disease 1983.|
|||Kroenke K, Spitzer RL, Williams JB, et al. Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment. Arch Fam Med 1994; 3(9): 774-9.
|||Cohen J. Statistical power analysis for the behavioral sciences 2nd ed. 1988.|
|||Karamustafalioglu O, Ozcelik B, Eds. Mental health in primary care [in Turkish] by the Ministry of Mental Health Department 2003.|
|||Yazici O, Oral ET, Vahip S, Eds. Depression treatment guideline [in Turkish] by The Mood Disorders Study Group of the Psychiatric Association of Turkey 2008.|
|||Karamustafalioglu O. Major depressive disorder, mental health care, and the use of guidelines in the Middle East. Journal of Clinical Psychiatry 2010; 71(Suppl E1 :e07).
|||Practice Guideline for the Treatment of Patients with Major Depressive Disorder 3rd ed. 2010.|
|||Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009; 117(Suppl. 1): S26-43.
|||Cipriani A, Koesters M, Furukawa TA, et al. Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev 2012; 10: CD006533.
|||Fukuchi T, Kanemoto K. Differential effects of milnacipran and fluvoxamine, especially in patients with severe depression and agitated depression: a case-control study. Int Clin Psychopharmacol 2002; 17(2): 53-8.
|||Hamdan A. Mental health needs of Arab women. Health Care Women Int 2009; 30(7): 595-613.
|||Okasha A. Mental health services in the Arab world. Arab Stud Q 2003; 25(4): 39-52.|
|||Becker S, Al Zaid K, Al Faris E. Screening for somatization and depression in Saudi Arabia: A validation study of the PHQ in primary care. Int J Psychiatry Med 2002; 32(3): 271-83.
|||Becker SM. Detection of somatization and depression in primary care in Saudi Arabia. Soc Psychiatry Psychiatr Epidemiol 2004; 39(12): 962-6.
|||Angst J. Sexual problems in healthy and depressed persons. Int Clin Psychopharmacol 1998; 13(Suppl. 6): S1-4.
|||Bonierbale M, Lançon C, Tignol J. The ELIXIR study: Evaluation of sexual dysfunction in 4557 depressed patients in France. Curr Med Res Opin 2003; 19(2): 114-24.
|||Sanchez C, Reines EH, Montgomery SA. A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike? Int Clin Psychopharmacol 2014; 29(4): 185-96.